We are always evolving in an ever-changing industry.

Official BRACELET-1 trial results indicate that adding the oncolytic virus immunotherapy pelareorep to paclitaxel chemotherapy warrants further investigation in HR+ HER2- metastatic breast cancer

Clinical Cancer Research has published a report detailing the safety and efficacy of pelareorep combined with paclitaxel chemotherapy, with or without the checkpoint inhibitor avelumab, for patients whose disease progressed after first-line treatment